MarketPulse

ANDA

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Catalyst Pharmaceuticals, Inc.

Catalyst Pharma Secures Patent Protection for FIRDAPSE Through 2035 Settlement

Catalyst Pharma settles patent litigation with Hetero Labs, blocking generic FIRDAPSE entry until 2035. Fourth major competitor settlement extends exclusivity.
CPRXrare diseasepatent settlement
GlobeNewswire Inc.GlobeNewswire Inc.··Nrx Pharmaceuticals

NRx Pharma Clears FDA Hurdle on Preservative-Free Ketamine Generic

NRx Pharmaceuticals advances preservative-free ketamine generic toward 2026 FDA approval, addressing supply shortages with U.S. manufacturing.
NRXPNRXPWFDA approvalregulatory milestone
GlobeNewswire Inc.GlobeNewswire Inc.··Nrx Pharmaceuticals, Inc.

NRx Pharmaceuticals to Unveil 2025 Results, Update on Breakthrough Psychiatric Drug Pipeline

NRx Pharmaceuticals to report 2025 results March 24, 2026, updating on FDA-designated ketamine and PTSD programs with significant clinical potential.
NRXPNRXPWfinancial resultsclinical-stage biopharmaceutical